Az angiogenezis gátlásának szerepe a vastagbél-és végbélrák kezelésé ben

Translated title of the contribution: Role of angiogenesis inhibitors in the treatment of colorectal cancer

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In our time, molecular targeted therapy plays a key role in the modern therapy of solid tumors. Of these modalities, in colorectal cancer monoclonal antibodies are introduced in routine use. In our article we provide an overview of the mechanism of action, place in treatment and efficacy of bevacizumab, an angiogenic inhibitor.

Original languageHungarian
Pages (from-to)139-144
Number of pages6
JournalMagyar Onkologia
Volume51
Issue number2
Publication statusPublished - 2007

Fingerprint

Molecular Targeted Therapy
Angiogenesis Inhibitors
Colorectal Neoplasms
Monoclonal Antibodies
Neoplasms
Therapeutics
Bevacizumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Az angiogenezis gátlásának szerepe a vastagbél-és végbélrák kezelésé ben. / Bodoky, G.

In: Magyar Onkologia, Vol. 51, No. 2, 2007, p. 139-144.

Research output: Contribution to journalArticle

@article{f55a4893a4e24ea59654d52a9aec4972,
title = "Az angiogenezis g{\'a}tl{\'a}s{\'a}nak szerepe a vastagb{\'e}l-{\'e}s v{\'e}gb{\'e}lr{\'a}k kezel{\'e}s{\'e} ben",
abstract = "In our time, molecular targeted therapy plays a key role in the modern therapy of solid tumors. Of these modalities, in colorectal cancer monoclonal antibodies are introduced in routine use. In our article we provide an overview of the mechanism of action, place in treatment and efficacy of bevacizumab, an angiogenic inhibitor.",
author = "G. Bodoky",
year = "2007",
language = "Hungarian",
volume = "51",
pages = "139--144",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "2",

}

TY - JOUR

T1 - Az angiogenezis gátlásának szerepe a vastagbél-és végbélrák kezelésé ben

AU - Bodoky, G.

PY - 2007

Y1 - 2007

N2 - In our time, molecular targeted therapy plays a key role in the modern therapy of solid tumors. Of these modalities, in colorectal cancer monoclonal antibodies are introduced in routine use. In our article we provide an overview of the mechanism of action, place in treatment and efficacy of bevacizumab, an angiogenic inhibitor.

AB - In our time, molecular targeted therapy plays a key role in the modern therapy of solid tumors. Of these modalities, in colorectal cancer monoclonal antibodies are introduced in routine use. In our article we provide an overview of the mechanism of action, place in treatment and efficacy of bevacizumab, an angiogenic inhibitor.

UR - http://www.scopus.com/inward/record.url?scp=35748940660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35748940660&partnerID=8YFLogxK

M3 - Article

C2 - 17660870

AN - SCOPUS:35748940660

VL - 51

SP - 139

EP - 144

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 2

ER -